Novo Nordisk · 20 hours ago
Senior ML Scientist - Molecular AI
Novo Nordisk is a leader in life science innovation, dedicated to improving human health. The Senior ML Scientist will contribute to the development and deployment of generative AI methodologies within computational drug design, collaborating with global teams to invent better molecules and accelerate therapeutic discovery.
BiotechnologyHealth CareMedicalPharmaceutical
Responsibilities
Support and drive integration of state-of-the-art generative AI methodologies within computational drug design
Optimize generative AI methodologies in conjunction with one or more design criteria for novel compound generation
Develop and implement new deep learning methods
Execute training, fine-tuning and inference of large models on GPUs
Deliver state of art methodologies and capabilities to the design and optimization of therapeutics by applying and developing the latest machine learning and AI algorithms
Work with ML scientists and engineers to guide the development of our ML models
Conceptualize approaches, identify capability gaps, and set goals within molecular AI
Represent AI and Digital Innovation as a technical/scientific lead on cross-functional research teams that include discovery, development and research IT organizations
Maintain a well-documented, reusable codebase, and traceable model history
Publish research in developing AI methods (example in ICLR, NeurIPS, ICML, Nature, Science, Cell etc.)
Work closely with experimental scientists, Digital Chemistry and Design, Research Engineer and other parts of the organization to driven the development and implementation of modern methods for molecular design
Actively participates in virtual global team meetings regularly
Participate in the evaluation of external and internal capabilities and facilitate collaborations with external partners
Present your results to an interdisciplinary team of experimental, modeling scientist and machine learning colleagues at company meetings and strategic program readouts
Qualification
Required
Master's degree, or PhD is highly preferred. Minimum of a Bachelor's degree required
Degree within machine learning, computer science, computational chemistry or a related quantitative discipline preferred
Master's Degree with 3+ years' relevant experience, or PhD with little to no experience, or a Bachelor's degree with 5+ years' relevant experience, can be considered
Experience with modern molecular design AI technology
Experienced in developing and implementing new deep learning methods
Experienced in PyTorch, training, fine-tuning and inference of large models on GPUs
Strong proficiency in Python and experience with PyTorch deep learning libraries and HPC
Knowledge of at least 2 of the following: deep learning, diffusion models, reinforcement or active learning, large language models related to the disciplines of molecular design
Excellent problem-solving skills and the ability to work independently as well as in a team environment
Preferred
Experience in pharmaceutical industry, healthcare industry, regulated medical device development or in another regulated field
Ability to execute own data science tasks while mentoring more junior Data Scientists in the development of their skills
Excellent oral and written communication skills
Detail oriented with strong documentation skills
Examples of your work, such as GitHub repository or publications that can showcase your skill
Benefits
Competitive compensation package
Support of a healthy work-life balance
Company
Novo Nordisk
Novo Nordisk is a healthcare company that produces and distributes insulin and other diabetes drugs to treat chronic diseases.
H1B Sponsorship
Novo Nordisk has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (25)
2024 (21)
2023 (13)
2022 (10)
2021 (9)
2020 (12)
Funding
Current Stage
Public CompanyTotal Funding
$22M2018-12-05Post Ipo Equity· $22M
1981-07-09IPO
Recent News
2026-01-13
The Philadelphia Inquirer
2026-01-12
Company data provided by crunchbase